Elevation of heat shock protein (HSP) levels is widespread in cancer and predicts a poor prognosis and resistance to therapy. We show that HSP elevation in tumor cells can be induced by the highly malignant factor heregulin b1 (HRGb1), which induces HSP expression through heat shock transcription factor 1 (HSF1). Inactivation of the hsf1 gene prevents HSP induction by HRGb1. HSP expression is induced through a cascade response initiated by HRGb1 binding to c-erbB receptors on the cell surface and which leads to the inhibition of intracellular HSF1 antagonist glycogen synthase kinase 3. HSF1 activated by this pathway plays a key role in the protection of cells from apoptosis and the mediation of anchorage independent growth by HRGb1, indicating a role for HSF1 in this tumorigenic pathway.
Introduction
Elevated heat shock protein (HSP) levels are observed in many cancers and signal a poor prognosis in terms of survival and response to therapy (Ciocca et al., 1993; Cornford et al., 2000; Blagosklonny, 2001; van't Veer et al., 2002; Tang et al., 2005) . HSP expression protects cells from spontaneous apoptosis during transformation in addition to apoptosis induced by therapy, and these mechanisms may underlie the role of HSP in tumor progression and resistance to treatment (Volloch and Sherman, 1999; Nylandsted et al., 2000a, b) . HSP transcription requires heat shock transcription factor (hsf1), which is itself overexpressed in cancer and plays a role in invasion and metastasis (Wu, 1995; McMillan et al., 1998; Hoang et al., 2000; Wang et al., 2004c) . As HSP are induced only under stress conditions in normal cells, some aspects of the malignant phenotype apparently cause HSP dysregulation (Lindquist and Craig, 1988) . We have examined the hypothesis that common oncogenic mechanisms activate the pathways leading to HSP overexpression, concentrating on the HRGb1/c-erbB ligand-receptor system (Sliwkowski et al., 1994; Aguilar et al., 1999; Rubin and Yarden, 2001; Tsai et al., 2003) . HRGb1 is a secreted factor that binds avidly to c-erbB-3 and c-erbB-4 receptors and causes 'horizontal signaling' in the plane of the membrane through the recruitment of c-erbB-2 by liganded c-erbB-3 or c-erbB-4 and receptor heterodimerization HRGb1 (Lupu et al., 1990; Sliwkowski et al., 1994) . c-erbB-2 lacks an HRGb1 binding domain but, when complexed to other c-erbB family members becomes a potent signaling molecule (Rubin and Yarden, 2001; Yarden and Sliwkowski, 2001 ). Formation of HRGb1-c-erbB complexes is followed by transmembrane signaling through tyrosine phosphorylation of the intracellular domains of c-erbB receptors, recruitment of adaptor proteins to phospho-tyrosine domains and the launching of intracellular signaling cascades (Rubin and Yarden, 2001) . Prominent among the latter include the phosphatidylinositol-3-kinase (PI-3-kinase) and extracellular signal regulated protein kinase (ERK) pathways (Li et al., 2001; Rubin and Yarden, 2001; Jackson et al., 2004) . We have examined the mechanisms underlying HSF1 activation by HRGb1 and the role of HSF1 in HRGb1 dependent generation of apoptosis resistance and ability to grow in anchorage independent conditions.
Results

HRGb1 induces HSP expression through hsf1 dependent transcription
We first examined the effects of HRGb1 on HSP expression in two human carcinoma cell lines (HeLa, MCF-7) and in mouse embryo fibroblasts (MEF) (Figure 1a ). HRGb1 exposure caused a prolonged increase in Hsp70 expression, which was observed until at least 48 h exposure in each cell line ( Figure 1a ). Hsp70 induction coincided with HSF1 increases in each cell line, suggesting a regulatory role for HSF1 downstream of HRGb1-binding ( Figure 1a) . Indeed, an essential role for the hsf1 gene in HSP synthesis following HRGb1 treatment is indicated by the experiments in Figure 1b . Exposure to HRGb1 increased HSF1 levels in wild-type hsf1 þ / þ MEF and led to elevated expression of Hsp70, Hsp60 and Hsp90, while in hsf1À/À cells, HSF1 was not detected, and we failed to observe significant increases in Hsp70 or Hsp90 levels after HRGb1 (Figure 1b) . Our experiments, therefore, carried out at HRGb1 levels within the physiological range (0.1-1 nM) indicate an essential role for hsf1 in HRGb1 induction of HSPs (Figure 1b ). There was however some evidence of Hsp60 induction in the hsf1À/À cells (Figure 1b) . Although the majority of HSP expression is due to HSF1, other factors may also be involved including the factor STAT1 (reviewed in Tang et al., 2005) . 
Signal transduction steps leading to hsf1 dependent activation of HSP expression by HRGb1
We next investigated the signal transduction steps linking HRGb1 binding to HSP synthesis. We used monoclonal antibodies Ab-7, Ab-5 and Ab-3, which block ligand access to, respectively, the c-erbB-2, c-erbB-3 and c-erbB-4 receptors on the cell surface to probe the role of these c-erbB receptors in HRGb1-induced HSP synthesis in hsf1 þ / þ MEFs (Figure 2a) . Preincubation with either Ab-5 or Ab-3 partially inhibited HSF1 and Hsp70 increases, suggesting potential roles for both c-erbB-3 and c-erbB-4 (Figure 2a) . Blockade of c-erbB-2 by pretreatment with Ab-7 severely reduced HRGb1 induction of HSF1 and Hsp70 expression, suggesting an essential role for this molecule (Figure 2a) . Inhibition of HSP expression by Ab-7 was not, however, as effective as the c-erbB-2 inhibitor AG-825, which causes almost complete inhibition of HRGb1-induced HSP expression ( Figure 2a ). The control antibody (anti-HDAC2), targeted to an intracellular epitope, failed to inhibit HRGb1 induction of HSF1 and Hsp70 (Figure 2a ). The potential involvement of both c-erbB-3/c-erbB-2 and c-erbB-4/c-erbB-2 heterodimers is thus suggested (Figure 2a) . Previous studies have shown that heregulin induces the formation of such heterodimers in target cells (Yarden and Sliwkowski, 2001) .
As activation of c-erbB-2 is essential for Hsp70 expression, we next investigated the role of c-erbB-2 kinase activity, and the downstream kinases that mediate two main arms of HRGb1/c-erbB-2 signaling, the PI-3 kinase and ERK pathways (Yarden and Sliwkowski, 2001; Jackson et al., 2004) . HRGb1 activated tyrosine phosphorylation of c-erbB-2 (assayed with both a pan-phosphotyrosine antibody and an antibody directed at residue Y1248 (Kim et al., 1999) ) and phosphorylation was inhibited by c-erbB-2 kinase inhibitor AG-825 (Figure 2b ). In addition, both PI-3 kinase and ERK kinase activity were induced by HRGb1 (Figure 2b ). To conveniently monitor PI-3 kinase, we examined the activity of the downstream kinase Akt1 (Stoica et al., 2003) . PI-3 kinase activation leads to accumulation of membrane phosphatidylinositol 3, 4, 5 phosphate (PiP3), an event that is correlated with Akt1 phosphorylation by the PiP3 associated protein kinase PDK1 (Stoica et al., 2003) . Akt1 was phosphorylated on serine residue S473 (Shin et al., 2002) after exposure to HRGb1 and was inhibited by the c-erbB-2 inhibitor AG-825 and PI-3 kinase inhibitor LY294,002, but not by the ERK inhibitor (Figure 2b) . The HRGb1 induced increases in HSF1, Hsp60, 70 and 90 were prevented by c-erbB-2 and PI-3 kinase inhibition, while ERK pathway inhibitor PD98059 did not prevent HSP expression (Figure 2c) . These experiments delineate a pathway involving c-erbB-2/PI-3 kinase/Akt kinase activity in HSF1 activation by HRGb1, but preclude the ERK arm of HRGb1 signaling (Figure 2a-c) . It was noted that each of the kinases activated by HRGb1 (c-erbB-2, Akt1, ERK1/2) is also induced in these cells by heat shock (Figure 2b , lane 6), suggesting a rationale for the confluence in effect on HSF1 between these fundamentally different agents. We have also studied these effects in the heregulin expressing breast carcinoma cell line MDA-MB-231 (deFazio et al., 2000) . These cells express a high baseline level of hsp70, which is further increased by HRGb1 ( Figure 2d ). As with the other cell lines, HRGb1 induced HSF1 and hsp70 expression and this effect was inhibited by the c-erb-B2 and PI-3 kinase inhibitors (Figure 2d ). We also examined the activities of two c-erbB-2 blocking antibodies herceptin and 2C4 (Jackson et al., 2004) . 2C4, which inhibits erbB-3/c-erbB-2 interactions and signaling through the PI-3 kinase pathway, strongly inhibited HSF1 and hsp70 expression (Figure 2d ). Herceptin, which acts on a different epitope in c-erbB-2 and is effective against cells overexpressing c-erbB-2, was less effective in inhibiting HSF1 and hsp70 expression (Figure 2d ). Interestingly, both AG-825 and anti-2C4 reduce HSF1 and hsp70 to below baseline levels in MDA-MB-231 cells, suggesting a role for heregulin/c-erbB-2 interactions in the basal expression of HSF1 and hsp70 by these cells (Figure 2d ). We next investigated the role of HRGb1 in transcriptional activation of HSF1, using a reporter construct based on the promoter of the strictly HSF1 induced HSP70B gene (pGLHSP70B) (Schiller et al., 1988) . Exposure to HRGb1 led to HSF1 transcriptional induction, which required the activity of the c-erbB-2 and PI-3 kinases but not ERK activity (Figure 2e ). Heat shock activated the reporter construct, as expected, although only a slight increase in HSP70B activity was observed when HRGb1 and heat shock were combined, suggesting the engagement of overlapping mechanisms by the two activators (Figure 2e ). These experiments further support the contention that HRGb1 activates HSP transcription through the c-erbB-2, PI-3K and Akt cascade. They do not however indicate directly how HSF1 is activated by HRGb1.
One property of HRGb1 potentially involved in HSF1 regulation is its known inhibition of glycogen synthase kinase 3 (GSK3) through Akt phosphorylation (Cross et al., 1995) . We showed previously that GSK3 directly phosphorylates HSF1 on serine 303, and thus represses its activity (Chu et al., 1996; Chu et al., 1998) . We therefore asked whether a mechanism involving inhibition of GSK3 through the HRGb1 cascade and consequent relief of HSF1 repression by GSK3 is involved in HSF1 activation. Indeed, exposure of cells to HRGb1 leads to GSK3a and b phosphorylation on inhibitory sites (serines 21 and 9, respectively), whose effect was blocked by c-erbB-2 and PI-3 kinase inhibitors (Figure 3a ). Direct GSK3 inhibition by LiCl was alone sufficient to increase HSF1 and Hsp70 levels, supporting a mechanism for GSK3 in negative regulation of HSF1 (Figure 3a , last lane) in line with previous studies (Chu et al., 1996 (Chu et al., , 1998 . No effects on HSF1 or Hsp70 expression were observed with addition of 2 mM myo-inositol, indicating the effects observed are through GSK3 rather than phosphoinositide signaling (not shown). Concomitant exposure of cells to LiCl and HRGb1 did not cause additive increases in HSF1 and Hsp70 expression, suggesting that the agents act on a common target, GSK3 (Figure 3a ). In addition, overexpression of GSK3a inhibits the ability of HRGb1 to trans-activate the HSP70B promoter and repression by GSK3a is overcome by addition of LiCl (Figure 3b ). LiCl alone also trans-activates HSF1, although it is evident that LiCl (at a concentration of 20 mM that blocks over 90% of GSK3 kinase activity; data not shown) is not as effective as HRGb1, suggesting that additional mechanisms may participate in HSF1 activation by HRGb1 (Figures 3a, b) .
Role of hsf1 in induction of anchorage independent growth by HRGb1
We next examined the role of the HRGb1/c-erbB-2/ HSF1 pathway in some of the steps associated with tumorigenesis, initially investigating ability of HRGb1 to promote anchorage independent growth in hsf1 þ / þ and hsf1À/À MEFs (Figure 4 ). Both cell types form colonies on tissue culture plastic under anchoragedependent conditions, although hsf1À/À cells divide more slowly (unpublished studies). Minimal evidence of colony formation in soft agar was seen in control hsf1 þ / þ and hsf1À/À MEFs in the absence of HRGb1 (Figure 4) . However, colonies of dividing cells grew out in hsf1 þ / þ cells exposed to HRGb1, and this effect was not observed in the hsf1À/À cells that failed to form colonies (Figure 4) . Inhibition of either c-erbB-2 activity or PI-3 kinase activity with, respectively, AG-825 and LY294,002 prevented HRGb1 induced colony formation in hsf1 þ / þ cells (Figure 4) . These experiments indicate that HRGb1-induced, c-erbB-2 dependent anchorage independent growth involves significant participation of hsf1.
Role of hsf1 in HRGb1-mediated protection from apoptosis
As previous studies show that hsf1 is a potent inhibitory factor in apoptosis, we next examined its role in the cytoprotective pathways controlled by HRGb1 (McMillan et al., 1998; Zhang et al., 2002) . Figure 5 shows the relative protection of cells from apoptosis by HRGb1 in cells treated with cis-platinum or heat shock in hsf1 þ / þ (WT) and hsf1À/À MEFs. cis-platinum induces apoptosis through the formation of DNA adducts and engagement of the p53/p73 and the Fas/ FasL pathways while c-erbB-2 and PI-3 kinase mediate cis-platinum resistance (Siddik, 2003) . Heat-induced apoptosis involves protein damage and activation of the c-jun kinase and p38 MAP kinase pathways (Gabai et al., 1997) . Generation of apoptosis was assayed by reduction in nuclear DNA content, and externalization of phosphatidyl serine (PS) on the outer leaflet of the plasma membrane (Fadok et al., 1992) . cis-platinum caused 55-60% of either cell type to undergo apoptosis as judged by decrease in DNA content to a sub-G 1 level, while HRGb1 pretreatment protected hsf1 þ / þ cells, reducing the level of apoptosis to 18% (Figure 5a ). Inactivation of hsf1 in the hsf1À/À MEFs led to a marked loss of protection from apoptosis by HRGb1 (Figure 5a ). Similar conclusions were drawn from parallel experiments using Annexin V staining (data not shown). As hsf1À/À MEFs lack thermotolerance (ability to develop heat resistance after a nontoxic heat shock), we examined whether HRGb1 mimics the priming dose of heat and induces hsf1 dependent thermotolerance (Fadok et al., 1992; Zhang et al., 2002) . Indeed, hsf1À/À MEFs were more sensitive to heat shock under basal conditions and show a large decrease in HRGb1-induced tolerance to heat shockinduced apoptosis (Figure 5b ). Loss of resistance in hsf1À/À MEFs was not, however, absolute and residual resistance to cis-platinum or heat shock was induced by HRGb1 exposure (Figure 5a, b) . This would be predicted from previous studies indicating that alternative antiapoptotic pathways are activated by HRGb1, which may operate independently from hsf1 and HSP (discussed below). We also examined the effects of the small molecule inhibitors of the HRGb1-HSF1 pathway, shown in Figure 2 , on cis-platinum mediated decrease in DNA content and PS externalization in wildtype MEF (Figure 5c, d) . Annexin V positive cells increased from 3% in controls to 52% after treatment with cis-platinum and pre-exposure to HRGb1 reduced this level of apoptosis to 24% (Figure 5c, d) . The cytoprotective effects of HRGb1 were significantly reduced by inhibition of c-erbB-2 and PI-3 kinase but not by antagonizing ERK activity (Figure 5c, d) . Similar results were obtained using the DNA content assay for apoptosis and in another cell type, MCF-7 (data not shown). It may be significant that the cytoprotective effects of HRGb1 protection by heat shock that also leads to HSP expression (Figure 5c , last lane and Figure 5d ). As both agents act through HSF1 and HSP expression, these similarities might be predicted. We also carried out similar experiments in MDA-MB-231 cells (Figure 5e ). cis-platinum exposure induced apoptosis in these cells and the apoptosis was strongly inhibited by AG-825, c-erbB-2 blocking antibodies anti-2C4 and Ab-7, although less effectively, by LY294,002 and herceptin. The effectiveness of these agents in overcoming the effects of HRGb1 on apoptosis (Figure 5e ) to platinum resistance is thus well correlated with effectiveness of the agents in inhibiting HSF1 and hsp70 expression (Figure 2d ).
Discussion
Our experiments indicate a novel hsf1 dependent pathway for HRGb1 induction of anchorage independent growth and resistance to apoptosis as well as a potential mechanism for the elevation of HSP in cancer. HRGb1 appears to be linked to HSP expression by its activation of HSF1 through inhibition of the constitutive kinase GSK3 through a pathway involving sequential activation of c-erbB-2, PI-3-K and Akt kinases (Figures 1-3) . Previous studies showed that GSK3 is a potent repressor of HSF1 through phosphorylation within a regulatory domain that constitutively represses the trans-activation domains, while strongly activating the same domains during stress (Green et al., 1995; Chu et al., 1996; Newton et al., 1996) . We also show that HRGb1 activates the ERK cascade shown previously to repress HSF1 when activated by serum or MEK2 overexpression (Chu et al., 1996; Wang et al., 2003) . Our experiments however indicate a mechanism through which HRGb1 bypasses the inhibitory effects of ERK. ERK1 has been shown to bind HSF1 and repress through phosphorylation on serine 307, secondary phosphorylation on serine 303 by GSK3, recruitment of 14-3-3 and cytoplasmic sequestration (Chu et al., 1996 (Chu et al., , 1998 Wang et al., 2004b) . High-affinity binding to 14-3-3 requires the dual phosphorylation of HSF1 at serines 303 and 307 (Wang et al., 2003) . Activation of the PI-3K/Akt pathway by HRGb1 appears to override the repressive effects of the ERK cascade through GSK3 inhibition and presumably HSF1 dephosphorylation at serine 303 (Figures 3a, b and 6 ). Similar events result from heat shock in which simultaneous activation of ERK and PI-3K may permit transcription of HSP genes through GSK3 inhibition (Figure 2c ) (Wang et al., 2004b) . Despite these similarities, however, the mechanisms involved in HRGb1 and stress-induced HSP expression diverge, as HRGb1 increases intracellular HSF1 levels while stress activation occurs post-translationally (Figures 1 and 2) (Sarge et al., 1993; Wu, 1995) . In addition, activation by HRGb1 did not lead to a major shift in the electrophoretic mobility of HSF1 (Figures 1 and 2) , contrasting with heat shock, which Figure 3 HRGb1 inhibition of GSK3 induces HSF1 activation and HSP synthesis. (a) MEF hsf1 þ / þ cells were serum starved for 24 h and then treated with (lanes 2-5) or without (lanes 1 and 6) HRGb1. Selected HRGb1 treated cultures were pretreated with 50 mM AG-825 (lane 3), 30 mM LY294,002 (lane 4) for 2 h or 20 mM LiCl (lane 5 and 6) for 24 h prior to HRGb1 treatment followed by quenching at 20 min or 24 h. Lanes 1-4 were treated with NaCl to minimize the salt effect. Cell lysates were analysed by immunoblot for HSF1, Hsp70, phospho-GSK-3a/b (Ser21/9), total GSK-3 a/b and b-actin. (b) Effect of GSK-3a expression on the activation of HSP70B promoter by heregulin and LiCl. MEF cells were transiently transfected with pGL-HSP70B (2 mg) alone or with expression plasmids pHSF1 (2 mg) and pMT2-GSK-3a (2 mg). In each culture, total amount of plasmid was adjusted to 4 mg with pGL6 control plasmid. Then cells were treated with HRGb1 alone, with HRGb1 plus LiCl or LiCl alone for 24 h as indicated. Cells were then lysed and luciferase activity was examined in the extracts. Mean relative luciferase activity, corrected for transfection efficiency, was expressed7the standard deviation (s.d.). Experiments were carried out three times with similar results Figure 4 Role of hsf1 in HRGb1-mediated anchorage-independent growth. (a) In total, 25 000 cells (MEF wt left, and MEF hsf1À/À cells, right) were plated on 0.5% agar in triplicate for each treatment group. The upper set of triplicate wells are from untreated controls, the second group incubated with HRGb1 and the lower two groups with AG-825 and LY294,002 plus HRGb1. Colonies were allowed to form for 4 weeks and then Â 20 phase contrast images were captured. In the MEF hsf1À/À cells, the AG-825 and LY294,002 experiment were not carried out. (b) Colonies composed of >10 cells were scored blind from three plates from each treatment group. Colony number is expressed as the mean7s.d. Figure 5 Role of hsf1 in protection from apoptosis by HRGb1. (a) MEF (wt and hsf1À/À) were grown to 60-70% confluence and serum starved for 24 h prior to incubation with or without HRGb1 for 24 h. Cells were next treated with cis-platinum II (CDDP, 100 mM)) for 6 h and then PI stained and analysed for DNA content by Flow Cytometry. Mean number of cells with sub-G 1 content7s.d. from three individual experiments is plotted. (b) MEF, wt and hsf1À/À cells were grown and treated as (a). To induce apoptosis cells were heat shocked at 471C for 1 h prior to development of apoptosis for 3 days at 371C. Cells were then PI stained and analysed for DNA content as in (a). (c) WT MEFs were grown as in (a) and treated with or without inhibitors (AG-825, PD98059 and LY294,002) for 2 h prior to HRGb1 treatment for 24 h. One set of cells was preheat shocked at 431C for 30 min before recovery at 371C for 6 h. Cells were then treated with cis-platinum as in (a) causes a quantitative shift in HSF1 mobility associated with hyperphosphorylation (Sarge et al., 1993; Chu et al., 1996) . The functional role of hyperphosphorylation in HSF1 activation is however not clear (Sarge et al., 1993) . GSK3 plays the role of constitutive repressor of many promalignant pathways including b-catenin, BCl 3 and androgen receptor signaling and appears to target its substrates towards proteosomal degradation via the binding of E3 ubiquitin ligases (Cardozo and Pagano, 2004; Ha et al., 2004; Karim et al., 2004; Viatour et al., 2004; Wang et al., 2004a) . Activation of promalignant signaling through heregulin or Wnt relieves such repression through Akt phosphorylation of GSK3 on inhibitory domains, thus permitting target proteins to escape degradation and to accumulate (Karim et al., 2004; Viatour et al., 2004; Wang et al., 2004a) . HSF1 may be regulated in a similar way, as both HRGb1 and LiCl inhibit GSK3 and lead to enhanced HSF1 accumulation (Figures 1-3) .
HRGb1 can cause homo-and heterodimerization between each member of the c-erbB family and our studies suggest that c-erbB-3/c-erbB-2 and c-erbB-4/ c-erbB-2 heterodimers may play essential roles in HSP expression (Yarden and Sliwkowski, 2001) (Figure 2a ). In addition, the requirement for the PI-3-kinase pathway in HSF1 activation would argue a key role for the c-erbB-3/c-erbB-2 complex, as c-erbB-3 couples very efficiently to PI-3-kinase (Yarden and Sliwkowski, 2001) . It is notable that none of the cell lines used in our studies express c-erbB-2 at markedly elevated levels (MA Khaleque and SK Calderwood, unpublished data), suggesting that HRGb1 activates HSF1 and HSP expression without the necessity for c-erbB-2 overexpression. c-erbB-2 overexpression is closely associated with malignancy, particularly in breast cancer (Hanahan and Weinberg, 2000; Yarden and Sliwkowski, 2001 ). However, heregulin can transform breast cancer cells independently of elevated c-erbB-2 levels (Tsai et al., 2003) . c-erbB-2 overexpression could, however, amplify the response of HSF1 to HRGb1, as in one CHO cell line examined in our studies, c-erbB-2 overexpression correlates with massive HSF1 activation and Hsp70 expression (MA Khaleque and SK Calderwood, in preparation) .
HRGb1 is a potent inducer of tumorigenesis and metastasis and this effect is correlated with ability to support anchorage independent growth in vitro (Aguilar et al., 1999; Tsai et al., 2003) . Our studies indicate that hsf1 plays a significant role in HRGb1-induction of anchorage independent growth (Figure 4 ). Other studies show that Hsp70 overexpression in fibroblast leads to anchorage independent growth, suggesting Hsp70 as a candidate for these effects of HSF1 (Volloch and Sherman, 1999) . Although hsf1À/À cells grow more slowly on tissue culture dishes and this may contribute to their lack of ability for anchorage independent growth, additional factors also may be involved as the hsf1À/À cells show no evidence of anchorage independent growth without or with HRGb1 (Figure 4 ). HSF1 may permit anchorage independent growth in HRGb1 treated cells through increased cell survival ( Figure 5 ). The triggering of antiapoptotic pathways is a common mechanism in tumor progression (Hanahan and Weinberg, 2000; Schulze-Bergkamen and Krammer, 2004) , and we have shown here that HRGb1 treatment protects cells from proapoptotic signals and requires hsf1 for full protection ( Figure 5 ). Previous studies have outlined a network of additional proapoptotic pathways downstream of heregulin, commonly involving the activation of PI-3 kinase and Akt (Yarden and Sliwkowski, 2001; Bhat-Nakshatri et al., 2002; Gottlieb et al., 2002; Venkateswarlu et al., 2002; Downward, 2004) . These include the induction of NFkB and MDM2, and repression of FOXO3a and the proapoptotic BCl 2 homologues BAX and BAD (Li et al., 2001; BhatNakshatri et al., 2002; Gottlieb et al., 2002; Venkateswarlu et al., 2002; Downward, 2004) . The HSF1 pathway constitutes another antiapoptotic mechanism induced by HRGb1 ( Figure 5 ). Hsp27, 70 and 90, which are versatile cytoprotective agents and suppress both intrinsic and extrinsic pathways of apoptosis at a number of steps may therefore number among the downstream effectors of HRGb1 cytoprotection (Beere, 2004) .
Our experiments for the first time link heregulin with the highly conserved heat shock response and suggest one potential mechanism for the widespread elevation in HSP expression in cancer. By coupling to the signal transduction pathways upstream of HSF1 regulation, HRGb1 is able to harness the powerful HSP gene expression program and utilize the potent cytoprotective effects of molecular chaperone genes, permitting growth in the hostile tumor microenvironment. 
Materials and methods
Chemicals and reagents
Recombinant human HRGb1 was purchased from Neo Markers (Fremont, CA, USA), c-erbB-2 inhibitor Tyrphostin AG-825 from Calbiochem (La Jolla, CA, USA), ERK inhibitor PD98059 from Cell Signaling Technology (Beverly, MA, USA), LY294,002 from Alexis Biochemicals (San Diego, CA, USA). HSP70B promoter luciferase reporter construct (pGL-HSP70B) have been described by us previously (Chen et al., 1997) . Herceptin and 2C4 were obtained from Genentech (CA, USA). Additional antibodies that specifically block HRGb1 binding to c-erbB-2 (Klapper et al., 1997) , cerbB-3 and c-erbB-4 (Chen et al., 1996) were selected for lack of direct activity on c-erbB kinase function and were obtained commercially (Neo markers).
Cell culture MCF7, HeLa, MEF and MEF hsf1À/À cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and antibiotics. MDA-MB-231 human breast cancer cells were obtained from ATCC and grown in Leibovitz's L-15 medium (ATCC) supplemented with 10% FBS at 371C without CO 2 . Cells were treated with 1 nM HRGb1 for 24 h or 48 h. In some cases, cells were treated with inhibitors (AG-825 (50 mM), PD98059 (50 mM) or LY294,002 (30 mM)) for 2 h prior to HRGb1 treatment. Heat shock was carried out at 431C for 30 min. To induce apoptosis, cells were either treated with cis-platinum II (cis-diamminedichloroplatinum, 100 mM) for 6 h or heat shocked at 471C for 1 h after the HRGb1 treatment.
Immunoblot analysis and antibodies
Cells were trypsinized, washed twice with cold phosphatebuffered saline (PBS) and lysed in modified RIPA buffer (Tris-HCL (50 mM, pH 7.4), NaCl (150 mM), NP-40 (1%), sodium deoxycholate (0.5%), SDS (0.1%) and EDTA (5 mM)) containing protease inhibitor cocktail (Boehringer Mannheim, GmbH, Germany). After centrifugation at 14 000 g for 10 min, the supernatant were used as cell extracts. Cell extracts were then subjected to SDS-PAGE and transferred onto nitrocellulose membranes (Schleicher & Schuell, Germany) using wet transfer apparatus (Bio-Rad Laboratories, CA, USA). Proteins were detected using a coupled second antibody-biotin/ avidin/chemiluminescence reaction.
The following antibodies were used in this study: polyclonal anti-HSF1, monoclonal anti-Hsp70, monoclonal anti-Hsp60, monoclonal anti-Hsp90 from Stressgen Biotechnologies (Victoria, Canada), monoclonal anti-b-actin from Sigma, (St Louis, MO, USA), monoclonal anti-c-erbB-2, polyclonal antiphospho c-erbB-2 (Tyr1248), polyclonal anti-Phospho AKT (Ser473) from Cell Signaling Technology (Beverly, MA, USA), polyclonal anti-c-erbB-3, polyclonal anti-c-erbB-4, polyclonal antiphospho-ERK (Tyr204) and polyclonal antiphosphotyrosine from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Luciferase assay
Luciferase and b-galactosidase activity assays were performed, according to the Promega protocol. Briefly, MEF cells (2.5 Â 10 5 cells/well) in six-well plates were transfected with 4 mg of pGL-HSP70B for 24 h using GenePorter2 transfection reagent (Gene Therapy System), according to the manufacturer's protocol. Then cells were heat shocked for 30 min at 431C or treated with inhibitors (AG-825, PD98059 or LY294,002) for 2 h prior to HRGb1 treatment. After 24 h, cells were lysed with luciferase cell culture lysis buffer and the cell lysate were used for luciferase assay. Luciferase activity was normalized to b-galactosidase activity. The results were expressed as the relative luciferase activity of the appropriate control.
Apoptosis assay
Inhibitors and/or HRGb1 treated MEF and MEF, hsf1À/À cells were either heat shocked at 471C for 1 h and allowed to recover at 371C for 3 days or treated with cis-platinum II (100 mM) for 6 h to induce apoptosis. The annexin V staining assay was performed according to the protocol provided by Southern Biotech. Briefly, cells were washed twice with cold PBS and resuspended in binding buffer to a concentration of 1 Â 10 6 to 1 Â 10 7 cells/ml. Then 10 ml of Annexin V-FITC were added to 100 ml of cells and incubated for 15 min on ice. Finally, 380 ml of cold binding buffer was added and the samples were analysed by flow cytometry. For Sub-G 1 DNA content assay, cells were washed twice with cold PBS and resuspended in cold PBS containing 70% ethanol and kept in À201C for 1 h. Then again washed with cold PBS and treated with propidium iodide (PI; Southern Biotech) containing RNase, incubated at 371C for 30 min and analysed by flow cytometry (Wang et al., 2004c) .
Anchorage independent growth
Cells (2.5 Â 10 4 ) were suspended in 1 ml of 0.33% Nobel Agar (DIFCO, Detroit, MI, USA) in DMEM with 10% FBS and antibiotics. Cell suspension was layered over 3.0 ml of 0.5% agar/DMEM in six-well plates. In total, 1 ml of fresh culture medium was added at 2 weeks. After 4 weeks, images of cell colonies growing under anchorage independent conditions were captured at Â 20 magnification with a Nikon microscope fitted with an Olympus camera. Colony formation was scored by counting equivalent areas in at least three plates from each condition. At least 300 colonies were counted in the controls under 'blind' conditions.
